ClinicalTrials.gg
RecruitingNCT05739149Updated Jan 22, 2026

A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers

An interventional study of Microvessel Ultrasound Examination and Skin Biopsy in Non-Healing Ulcer of Skin, Non-healing Wound and Lower Extremity Wound, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 141 studies in Ulcer with a site in United States — 24 open to participants now, 27 under way, none of them phase 3. Ulcer · United States.

Planned enrollment
108th of 124
10 · median 95
Started
2023
with 2 others
No phase
60 of 141
12 open now
Primary completion
2026-12
later than 10 of 26 live
Registered
115th of 141
by date

Among the 141 studies in Ulcer with a site in United States, this one is the 108th largest by planned enrollment of the 124 interventional ones that give a count, is one of 3 that started in 2023, is one of 60 with no phase, reaches primary completion later than 10 of the 26 other live ones, and was the 115th registered.

Ulcer

360 studies on the registry are indexed under Ulcer; 61 are open to participants now.

Browse Ulcer studies →

Open to participants now

24 of the 141 studies in Ulcer with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Ulcer with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to explore the use of high-resolution microvessel ultrasound imaging system to look for scarring and to monitor wound healing and to see if treatment affects the amount of tiny vessels and circulation around the wound.

03

Conditions studied

  • Non-Healing Ulcer of Skin
  • Non-healing Wound
  • Lower Extremity Wound

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic wound in the course of diabetic foot ulcers and/or lower extremity venous ulcers with duration of at least 6 weeks and the wound surface not less than 2 sq. cm and not greater than 15 sq. cm, without evidence of active infection of the wound at the time of qualification to participate in the study
  • Meets criteria for stalled chronic wound defined as less than 50% reduction in wound size after 30 days of standard of care management.
  • For chronic venous ulcers, ultrasound demonstrates venous reflux >0.5 seconds
  • Satisfactory blood glucose control - fasting not more than 110 mg%, \<6.5%
  • Satisfactory blood supply to the wound verified by the measurement of the oxygen level of the foot tissue (TCPO2 > 30mmHg) in patients with neuropathic etiology of diabetic foot syndrome
  • In the case of the patients with the wounds of ischemic component, the condition for qualification is a clinical improvement of the limb's blood supply as a result of the revascularization procedure documented by ultrasound.
  • Ankle-brachial index (ABI) ≥ 0.8

Exclusion criteria

Exclusion Criteria:

  • Acute wound with duration less than 6 weeks
  • Evidence of active infection or on antibiotics
  • Smoker
  • For chronic venous ulcers, ultrasound demonstrates venous reflux \<0.5 seconds
  • Unsatisfactory blood glucose control - fasting more than 110 mg%, \<6.5%
  • Poor blood supply to the wound verified by the measurement of the oxygen level of the foot tissue (TCPO2 \< 30mmHg) in patients with neuropathic etiology of diabetic foot syndrome
  • Ankle-brachial index (ABI) \< 0.
  • Pregnancy
  • Known allergy to lidocaine
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Microvessel Ultrasound Imaging for Chronic Ulcers

    Subjects with chronic diabetic ulcers and venous ulcers will undergo wound debridement and treatment as standard of care and receive research microvessel ultrasound examination and two skin biopsies

    Diagnostic Test: Microvessel Ultrasound Examination · Procedure: Skin Biopsy

Interventions

  • Diagnostic testMicrovessel Ultrasound Examination

    Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin

  • ProcedureSkin Biopsy

    Dermatology will remove a small piece of skin from the affected ulcer area and control skin

06

What researchers measure

Primary outcomes

  1. Microvessel imaging

    Number of subject's microvessel imaging results that correlate to the standard of care clinical assessment of wound healing

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 44 non-industry interventional studies with no phase under Ulcer, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 64. This study's planned 36 months is above that.

Counting every sponsor, half of 69 studies reached it within 25 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2023
First posted
Feb 22, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 10, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05739149
Lead sponsor
Mayo Clinic
Responsible party
Michael R. Moynagh (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Feb 22, 2023
Start date
Dec 1, 2023
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
Jan 22, 2026

Study contacts

Michael R Moynagh, MD
Contact
moynagh.michael@mayo.edu
507-266-4755
Michael Moynagh, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion